All Posts

Discover products that support nonclinical safety evaluation in drug development.

Discover products that can aid in predicting human toxicity from preclinical data.

Discover essential products to aid in navigating ICH guidelines for nonclinical studies.

Discover products that can deepen your insights into toxicology and regulatory approval.

Discover products to support your molecular biology safety assessments.

Discover products to support your nonclinical toxicology studies and drug development efforts.

Discover products that can aid in identifying drug toxicity mechanisms.

Discover products that can assist in nonclinical safety and toxicology assessments.

Discover products that support pharmacokinetics studies in drug development.

Discover products that support nonclinical safety and toxicology studies.

Discover products that support good laboratory practices in drug development.

Navigating the regulatory maze of Investigational New Drug (IND) submissions can feel overwhelming. You have a promising therapy, but the path to clinical trials is littered with complex requirements and strict timelines. What if you could simplify this journey? That’s where expert guidance comes in. With the right support, you can streamline your IND submission, avoid costly delays, and focus on what matters most - advancing your drug development. Why IND Submission Expert G

Discover products to enhance your nonclinical safety assessment processes.

Discover products that support toxicology in drug discovery and nonclinical safety.

Discover products that support your knowledge of nonclinical safety in drug development.

TK data gets thrown into reports as a table and a figure. It rarely gets treated as what it actually is — one of the most powerful interpretive tools in your nonclinical program. TK underpins every dose justification and exposure margin calculation you make. Get it right and your NOAEL is bulletproof. Get it wrong and your entire tox package starts to unravel. This issue breaks down the good, the bad, and the ugly of TK profiles.

Most nonclinical teams spend a lot of time thinking about which studies to run. Very few spend enough time thinking about when. Study sequencing is one of the most consequential — and most underestimated — decisions in IND-enabling development. Get the order right and your program builds on itself. Get it wrong and you're defending conclusions built on shaky ground. This issue breaks down the 3 sequencing mistakes I see most often.

"No major findings" is one of the most reassuring phrases in nonclinical development — and one of the most dangerous. It describes what wasn't observed. It doesn't interpret what the study actually resolved. Once that phrase enters the conversation, attention shifts, assumptions harden, and questions stop being asked. This issue unpacks why clean studies require more interpretation, not less.

There's a point in nonclinical development where data stop helping a program and start working against it. In toxicology we call this inflection point hormesis — low doses help, high doses harm. The same dynamic applies to data. Early on, data reduce uncertainty. Beyond a certain threshold, they complicate interpretation and replace judgment instead of supporting it. This issue unpacks what happens when data accumulation crosses its toxic threshold.